CTOs on the Move

Apricus Biosciences Inc.

www.apricusbio.com

 
Apricus Biosciences Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in San Diego, CA. To find more information about Apricus Biosciences Inc., please visit www.apricusbio.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.apricusbio.com
  • 6330 Nancy Ridge Dr Ste 103
    San Diego, CA USA 92121-3220
  • Phone: 858.222.8041

Executives

Name Title Contact Details

Similar Companies

Webmedx

Webmedx is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shamrock Medical Inc

Shamrock Medical Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diversified Clinical Services

Diversified Clinical Services is a privately held corporation headquartered in Jacksonville, Florida, with offices in Tustin, CA and the Woodlands, TX. The company was formed as a result of a merger between Diversified Therapy and Praxis Clinical

MDNewsline

Medical News & Updates on healthcare disparities and cultural competency for Health Care Professionals & Advocates

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.